News | Cardiovascular Clinical Studies | August 12, 2022

Johns Hopkins Researchers Find Link Between Dementia and Atrial Cardiopathy

Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at increased risk of developing dementia, according to new research led by Johns Hopkins Medicine.

August 12, 2022 —  Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at increased risk of developing dementia, according to new research led by Johns Hopkins Medicine

The findings were published Aug. 10 in the Journal of the American Heart Association

More than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year, according to the World Health Organization. Dementia is the loss of cognitive functioning — thinking, remembering and reasoning — to such an extent that it interferes with a person’s daily life and activities. 

Johns Hopkins Medicine researchers studied 5,078 older adults living in four U.S. communities: Washington County, Maryland; Forsyth County, North Carolina; northwestern suburbs of Minneapolis; and Jackson, Mississippi. The participants did not have dementia when the study began. The researchers sought to determine if there was a difference in the number of people who developed dementia by comparing a group that had markers of left atrial (one chamber of the heart) dysfunction versus those who did not. 

Stroke and atrial fibrillation are two medical conditions tied to atrial cardiopathy [dysfunction of the atrium, or left upper cavity of the heart],” says study author Michelle Johansen, M.D., Ph.D., an assistant professor of neurology at the Johns Hopkins University School of Medicine and an attending physician in The Johns Hopkins Hospital’s cerebrovascular division. “We looked to see if we could find any association between the left atrium and dementia that was mediated by, or as a result of, the development of either one of these conditions.” 

In the study, Johansen and her colleagues found that the prevalence of atrial cardiopathy among participants was 34%. The mean age of the participants was 75, and 59% were female adults and 21% were Black adults.

Johansen says the team looked at three markers that could be obtained from routine medical tests to measure the function of the left atrium. These include an echocardiogram (a test of the heart action using ultrasound waves to produce a visual display), an electrocardiogram (a record or display of a person’s heartbeat) and a blood marker that determines how the heart functions. Using these three tests, the team established a definition of atrial cardiopathy and then grouped participants into whether they met this definition.

"We found that patients who had atrial cardiopathy as we defined in our study had a higher hazard, or rate, of dementia over time versus those who did not have atrial cardiopathy,” Johansen says.

She also says this is believed to be the first time this has been shown to be the case. Additionally, the team found that the effect was not mediated through either atrial fibrillation or stroke despite that these medical conditions are known to be associated with dementia

Johansen says the study is important for people without symptomatic cardiac disease. Those with rather subtle changes in the left atrium are at an increased risk of dementia even after controlling for other vascular risk factors. In future research, the team hopes to understand the mechanism behind this association better. 

For more information: https://www.hopkinsmedicine.org/


Related Content

News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
Subscribe Now